Medigen Biotechnology (3176) — Cash Flow-to-Debt Ratio
Medigen Biotechnology (3176) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of NT$-18.91 Million could theoretically repay 0% of its total liabilities (NT$1.45 Billion) in one year. Explore 3176 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medigen Biotechnology Cash Flow-to-Debt Ratio (2003–2024)
Historical debt coverage capacity for Medigen Biotechnology across 12 annual periods. Also explore total assets of Medigen Biotechnology for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Medigen Biotechnology (2003–2024)
Year-by-year debt coverage analysis for Medigen Biotechnology. For market capitalisation and broader financial context, see Medigen Biotechnology stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | NT$37.92 Million | NT$1.67 Billion | ▲ +114.1% |
| 2023 | -0.16x | NT$-569.40 Million | NT$3.53 Billion | ▲ +49.8% |
| 2022 | -0.32x | NT$-1.13 Billion | NT$3.51 Billion | ▼ -210.1% |
| 2021 | 0.29x | NT$517.45 Million | NT$1.77 Billion | ▲ +171.8% |
| 2020 | -0.41x | NT$-671.38 Million | NT$1.65 Billion | ▼ -55.4% |
| 2019 | -0.26x | NT$-560.17 Million | NT$2.14 Billion | ▲ +18.3% |
| 2018 | -0.32x | NT$-529.82 Million | NT$1.66 Billion | ▼ -18.6% |
| 2017 | -0.27x | NT$-455.62 Million | NT$1.69 Billion | ▲ +26.1% |
| 2016 | -0.36x | NT$-468.61 Million | NT$1.28 Billion | ▼ -227.8% |
| 2015 | 0.29x | NT$294.18 Million | NT$1.03 Billion | ▼ -81.7% |
| 2005 | 1.56x | NT$80.72 Million | NT$51.78 Million | ▼ -61.5% |
| 2003 | 4.04x | NT$445.46 Million | NT$110.16 Million | — |